

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
阿里健康信息技術有限公司
(Incorporated in Bermuda with limited liability)
(Stock code: 0241)

**RE-DESIGNATION OF DIRECTOR,
CHANGE OF CHIEF EXECUTIVE OFFICER AND
AUTHORIZED REPRESENTATIVE
AND
APPOINTMENT OF EXECUTIVE DIRECTOR**

**RESIGNATION OF CHIEF EXECUTIVE OFFICER AND AUTHORIZED
REPRESENTATIVE, AND RE-DESIGNATION OF DIRECTOR**

The board of directors (the “**Board**”) of Alibaba Health Information Technology Limited (the “**Company**” or “**Alibaba Health**”) announces that Mr. Wang Lei (“**Mr. Wang**”) has resigned as the chief executive officer of the Company, and will cease to act as one of the authorized representatives of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), with effect from March 29, 2018 (the “**Resignation**”). Mr. Wang has decided to hand over executive responsibilities at the Company to re-join the Company’s holding company Alibaba Group Holding Limited and its subsidiaries (collectively, the “**Alibaba Group**”), but will continue to serve as a non-executive Director on the Board of the Company. Mr. Wang has confirmed that there are no disagreements with the Board, nor are there any matters in relation to his Resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The biography of Mr. Wang is set out below:

Mr. Wang Lei, aged 38, was appointed as the Company’s executive Director and chief executive officer on April 17, 2015. Prior to this position, Mr. Wang was the general manager of Alibaba Group’s Taobao Diandian business from September 2013. Mr. Wang

held various positions within Alibaba Group since he joined Alibaba Group in 2003, including senior director of the B2B advertising service department and senior director of the mobile Internet business department's O2O workshop. Mr. Wang holds a bachelor's degree in precision instruments from China Jiliang University. Mr. Wang is a director of certain subsidiaries of the Company, and a consultant to Alibaba Group.

In connection with the re-designation, Mr. Wang has entered into an appointment letter with the Company under which he has agreed to act as a non-executive Director for a term of one year commencing from March 29, 2018, which is renewable for a one-year period upon expiry of each term. Mr. Wang is subject to retirement by rotation and re-election as a Director in accordance with the bye-laws of the Company and the Listing Rules. According to the appointment letter, Mr. Wang will not be receiving any director's fee or remuneration for acting as non-executive Director.

Subject to vesting, Mr. Wang is interested in 737,000 ordinary shares and 14,413,000 shares underlying the 8,632,000 options and 5,781,000 restricted share units granted to him in accordance with the share award scheme adopted by the Company at the special general meeting held on November 24, 2014.

Save as disclosed above, Mr. Wang has not held any other directorships within any public listed companies in the past three years and is not connected with any directors, senior management or substantial or controlling shareholders of the Company. Mr. Wang has confirmed that there is no other information to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no matters that need to be brought to the attention of the Shareholders.

APPOINTMENT OF NEW EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND AUTHORIZED REPRESENTATIVE

The Board is pleased to announce the appointment of a new executive Director, chief executive officer and authorized representative of the Company, Mr. Shen Difan (“**Mr. Shen**”), with effect from March 29, 2018.

The biography of Mr. Shen is set out below:

Mr. Shen Difan, aged 39, was, prior to his current position, the general manager of Alibaba Group's AliExpress business from March 2012, and led the rapid expansion of AliExpress, growing Alibaba Group's overseas brand influence. Mr. Shen joined Alibaba Group in 2004 and had held various positions in Alibaba Group, including in relation to B2B product operations, and in the security department and advertising product department. Mr. Shen holds a bachelor's degree in computing from Yantai University. Mr. Shen currently serves as a director of certain subsidiaries of Alibaba Group Holding Limited but will resign as a director of such companies as soon as practicable. Mr. Shen will also act as a consultant to Alibaba Group.

As at the date of this announcement, Mr. Shen has entered into an appointment letter with the Company in relation to his appointment as an executive director and chief executive officer of the Company for a term of one year commencing from March 29, 2018, which is renewable for a one-year period upon expiry of each term. Mr. Shen is subject to retirement by rotation and re-election as a Director in accordance with the by-laws of the Company and the Listing Rules. The appointment letter does not specify Mr. Shen's remuneration, and his remuneration is expected to be determined by the Board with reference to his experience and prevailing market levels. The Company will disclose details regarding Mr. Shen's remuneration as soon as practicable.

Save as disclosed above, Mr. Shen has not held any other directorships within any public listed companies in the past three years and is not connected with any directors, senior management or substantial or controlling shareholders of the Company. Mr. Shen has confirmed that there is no other information to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no matters that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its gratitude to Mr. Wang for his contribution to the Board as executive Director and chief executive officer and to welcome Mr. Shen to the Board.

In respect of Mr. Wang's resignation as chief executive officer and Mr. Shen's appointment, the chairman of the Board Mr. Wu Yongming said:

“We are grateful to Wang Lei for his achievements and contributions to Alibaba Health as chief executive officer. During his tenure, Wang Lei has put together an excellent management team at Alibaba Health and built a complete pharmaceutical and healthcare business platform, successfully completing this phase of the Company's strategic development to lay a solid foundation for the Company's future rapid growth. At the same time, we welcome Shen Difan in his new role, and hope that he will be able to leverage on his strong Internet platform operations capabilities to lead the Company in the next stage of consolidating its business strengths and expanding new markets, and to continue to intensify the development of Alibaba's important “Double H” strategy.”

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
WU Yongming
Chairman of the Board

Hong Kong, March 29, 2018

As at the date of this announcement, the Board comprises eight Directors, of whom (i) one is an executive Director, namely, Mr. SHEN Difan; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei, Mr. KANG Kai and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.